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Abstract: Gelatin has been used for many years in pharmaceutical formulation, cell culture 
and tissue engineering on account of its excellent biocompatibility, ease of processing and 
availability at low cost. Over the last decade gelatin has been extensively evaluated for 
numerous ocular applications serving as cell-sheet carriers, bio-adhesives and bio-artificial 
grafts. These different applications naturally have diverse physical, chemical and biological 
requirements and this has prompted research into the modification of gelatin and its 
derivatives. The crosslinking of gelatin alone or in combination with natural or synthetic 
biopolymers has produced a variety of scaffolds that could be suitable for ocular 
applications. This review focuses on methods to crosslink gelatin-based materials and how 
the resulting materials have been applied in ocular tissue engineering. Critical discussion of 
recent innovations in tissue engineering and regenerative medicine will highlight future 
opportunities for gelatin-based materials in ophthalmology. 
OPEN ACCESS 
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1. Introduction 
The emergence of regenerative medicine therapies in ophthalmology has provided potential 
treatment pathways for conditions which previously were untreatable [1–4]. One of the major 
challenges faced by those working in the area has been to develop cytocompatible, surgically 
deliverable scaffolds with good optical properties, which can be consistently produced at low cost. In 
the case of cell therapies, an additional requirement is that these scaffolds must reproducibly support 
sensitive populations of therapeutic cells [5,6]. Recent research has focused upon natural polymer 
proteins due to their similarity to native tissues [7–9]. 
Gelatin, a protein based material derived from the hydrolysis of collagen, has been well utilised in 
this area on account of its biodegradable, biocompatible nature and its commercial availability at low 
cost [10]. It has been shown to have advantages over its parent protein, which include lower 
immunogenicity [11–14], better solubility in aqueous systems and a sol-gel transition at 30 °C [15]. In 
addition, gelatin can be crosslinked or modified with the inclusion of other materials to significantly 
alter its mechanical and biochemical properties. 
Research into the use of crosslinked gelatin-based materials in ocular repair has occurred in three 
distinct areas: bio-adhesives [16,17], structural scaffolds [18,19] and cell-sheet carriers [20,21] with an 
extensive body of research focused on the latter. 
1.1. Gelatin as a Biomaterial 
Gelatin exists as a mixture of water soluble protein fragments, comprised of the same amino acid 
sequences as collagen, from which it is derived [22]. Collagen differs from gelatin in that it contains 
far more tertiary structure, leading to a lower aqueous solubility [23]. Gelatin can be manufactured 
from a variety of animal collagens with the most commonly used forms in tissue engineering derived 
from porcine [24,25], fish [26] and bovine [27] tissues. Gelatin output quality can be dependent on the 
pH, temperature, and extraction time used in collagen processing [28]. Parameters such as molecular 
weight and isoelectric point (IEP) can be changed depending on the processing conditions [27,29]. 
Gelatin can be obtained under acidic and alkaline pre-treatment conditions which give rise to type A 
gelatin (IEP at pH 8–9) and type B gelatin (IEP at pH 4–5) respectively [28]. 
The Bloom strength of gelatin is a measure of gelation properties of the material and will largely be 
dictated by the triple-helix content [30–33]. Specifically the Bloom strength refers to the number of 
grams required for a 0.5 inch diameter probe to deflect a set gel by 4 mm, typically ranging from 30 to 
300 g. It has been proposed that Bloom strength is related to the proline-hydroxyproline content of the 
resultant gelatin [34], which in turn will be determined by the composition of collagen being  
processed [28]. Typically fish gelatins possess lower levels of these important amino acids resulting in 
gelatin with lower gelling temperatures and lower bloom strength than those derived from  
mammals [35]. When using gelatin of porcine or gelatin source, religious beliefs (e.g., Islam, Judaism, 
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Jainism and Hinduism) should be acknowledged. However, despite this mammalian gelatin has found 
wide use as an excipient in pharmaceutical processing [36], as a stabilizer in vaccines [37], and as an 
agent in food processing for many years [28]. 
The common use of gelatin in these applications has been shown in a very small number of cases to 
raise hypersensitivity to the protein [37,38]. However, reports of clinical reactivity to porcine and 
bovine gelatin have been relatively uncommon [39–41]. Immune reactivity has been reported  
to vary with molecular weight of gelatin being employed [42,43]. Thus considering the mode of 
processing and the specification of gelatin used will be important in clinical translation of tissue 
engineered constructs. 
Mammalian gelatin, is rich in domains that bind to cell-surface receptors and to other extracellular 
matrix (ECM) proteins, such as ﬁbronectin, offering an excellent substrate for attachment of adherent 
cells [44]. In addition, gelatin matrices can undergo collagenase mediated digestion, which allows 
biologically driven remodeling of the matrices in vivo [18]. Gelatin-based materials often have good 
transparency given their high water-content making them ideal for use in repair of ocular tissues in the 
visual axis [45]. 
1.2. Gelatin vs. Collagen 
Collagen has been shown to be a suitable material for multiple applications in ophthalmology [7,46–49] 
however it is not without drawbacks. The main disadvantage of collagen is the potential antigenic and 
immunogenic response that can be elicited from its in vivo use [50]. Antigenicity of exogenous 
collagen is attributable both to the helical structures as well as central and terminal amino acid 
sequences. Gelatin has been reported to reduce the potential of an antigenic response in vivo, relative 
to its parent protein. Unlike collagen, gelatin is deficient in both tyrosine and tryptophan, and contains 
only low levels of phenylalanine [51]. Consequently, gelatin has a lower potential for the formation of 
aromatic radicals which have been linked to increased antigenic responses [52]. 
Issues with collagen’s immunogenic response have been circumvented through the use of 
recombinant human collagens (RHC), although these are costly to produce [53,54]. Chemically 
crosslinked RHC hydrogels have been used successfully to treat patients suffering corneal thinning [55]. 
Transplanted RHC constructs remained stable for 24 months post-surgery without the need for 
systemic immunosuppression [56].  
The benefits of lower immunogenicity, cost and aqueous solubility make gelatin an excellent choice 
of base biomaterial for ocular tissue engineering applications. This review will take stock of the variety 
of different ways gelatin has been crosslinked and processed to create biocompatible scaffolds for 
ocular tissue engineering. 
2. Crosslinking Strategies 
Both gelatin and collagen have some solubility in aqueous systems, and can be rapidly digested by 
collagenases produced by many different cell types, both in vivo and in vitro. This is a significant 
drawback in terms of their utility in tissue engineering. To improve the physical properties of these 
proteins, crosslinking strategies have been developed to obtain materials with lower aqueous solubility, 
higher mechanical strength and stability against enzymatic degradation [51]. It has also been reported 
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that crosslinking can significantly reduce the antigenicity of these materials, through significantly 
modifying major antigenic sites [57]. However, more recent accounts have reported that transplantation 
of xenogeneic glutaraldehyde crosslinked heart valves produced an increased antigenic response 
relative to uncrosslinked valves [58]. Currently, without substantiated evidence, it is difficult to gauge the 
in vivo effect of crosslinking on immunochemical responses to gelatin and collagen. For a review of 
collagen crosslinking processes readers are directed to an excellent review by Parenteau-Bareil et al. [59]. 
Crosslinking methods reported in the literature have included: chemical crosslinking; enzymatic 
crosslinking; and physical crosslinking. For an overview of the different crosslinking approaches that 
have been utilised for gelatin in ocular tissue engineering see Table 1. 
2.1. Chemical Crosslinking 
To date, chemical crosslinking is the most popular approach to crosslink gelatin. Chemical 
crosslinking agents can be differentiated into “non-zero-length” (covalently linking amine residues) 
and “zero-length” (covalently linking carboxylic acid and amine residues), depending on whether the 
linking reagent contributes to the molecular structure of the crosslinked product. 
2.1.1. Non-Zero-Length Crosslinking 
Non-zero-length crosslinking introduces reagents to bind the gelatin network structure, typically by 
bridging the free amine groups of lysine or the free carboxylic acid residues of aspartic and glutamic 
acid in the gelatin structure. Several crosslinking reagents have been used to this end, including 
aldehydes (such as glyceraldehyde [60], formaldehyde [32] and glutaraldehyde (GA) [61]), 
polyepoxides [62], isocyanates [63] and natural products such as genipin [64,65].  
GA has been used frequently on account of its fast reactions and high solubility in aqueous  
solution [60,66]. GA reacts with the α-amino groups of lysine to create a Schiff base between the 
polymer chains. GA crosslinking has for many years been the gold-standard for crosslinking porcine 
tissue derived heart valves for transplantation. Such devices have seen relatively low incidence of 
thromboembolism and good haemodynamic performance [67]. In comparison to crosslinking with 
other aldehydes, such as formaldehyde [32] and glyceraldehyde [60], the crosslinks made using GA 
are highly stable [68]. Crosslinking in this way can dramatically alter the mechanical and biological 
properties of gelatin as demonstrated in a study carried out on films using different concentrations of 
GA [66]. GA crosslinked gelatin has been investigated in ocular tissue engineering, with compatibility 
evaluated using corneal endothelial and stromal cells (see Table 1) [12,69]. 
 
Materials 2014, 7 3110 
 
Table 1. Application of crosslinked gelatin in ocular tissue engineering. 
Type of crosslinking Gel composition Cell type Target tissue 
Clinical 
application 
Validation of biocompatibility 
Reference 
in vitro experiments in vivo experiments 
Chemical: 
non-zero-
length 
GA 10% Gelatin 
Primary 
corneal 
endothelial 
Corneal 
endothelium 
Endothelial cell 
sheet delivery 
Proliferation assay; 
live/dead;  
PIC expression 
IOP; cell morphology corneal 
thickness; 
[12] 
GA 10% Gelatin 
Keratocyte 
sphere 
Corneal 
stroma 
Stromal tissue 
graft 
ICC; gene expression;  
histology 
Biomacroscopy; histology; 
IHC 
[69,70] 
GA 
Gelatin and 
Chitosan 
Limbal 
epithelial cells 
Limbal 
epithelium 
Limbal Epithelial 
Stem Cell Carrier 
Proliferation assay; 
gene expression; ICC 
– [13] 
GA 10% Gelatin 
ARPE-19 
Cells 
RPE 
RPE Sheet 
Delivery 
Proliferation assay  
PIC expression 
– [71] 
Chemical: 
zero-length 
EDC 10% Gelatin 
Primary 
Corneal 
Endothelial 
Corneal 
Endothelium 
– 
Proliferation assay; 
Live/Dead; PIC 
expression 
IOP; Corneal Thickness; 
Morphology; Biomacroscopy; 
h-Proline in aq. humor; 
Histology; IOP; 
[12,72] 
EDC 10% Gelatin 
ARPE-19 
Cells 
RPE 
RPE Sheet 
Delivery 
Proliferation; 
Live/Dead;  
PIC expression; 
glutamate uptake; 
– [21] 
EDC 15% Gelatin 
Primary 
Corneal 
Endothelial 
Corneal 
Endothelium 
Endothelial Cell 
Sheet Delivery 
Proliferation assay; 
Endothelial Gene 
Expression 
Endothelial Cell Density [20] 
EDC/NHS 
10% Freeze dried 
crosslinked with 
CS 
Primary 
Corneal 
Stromal Cells 
Corneal 
Stroma 
Stromal Tissue 
Graft 
Adhesion assay; 
Proliferation assay;  
Collagen and GAG 
production; gene 
expression; Cell 
morphology 
– [18,19] 
Enzyme 
m-TG 
22.5% Gelatin + 
20mg/mL m-TG 
– Neural Retina 
Retinal 
Reattachment 
– Histology [16] 
m-TG 
12% Gelatin/10.8 
IU/mL  
m-TG 
– Neural Retina 
Retinal 
Reattachment 
– 
Fundus Examination; 
Histology; OCT 
[17] 
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Table 1. Cont. 
Type of  
crosslinking 
Gel 
composition 
Cell type Target tissue 
Clinical 
application 
Validation of biocompatibility 
Reference 
in vitro experiments in vivo experiments 
Physical 
Dehydration 10% Gelatin 
Primary Corneal 
Endothelial 
Corneal 
Endothelium 
Endothelial Cell 
Sheet Delivery 
ICC; Live/Dead; 
Morphology (SEM and 
TEM);  
Western Blot 
Biomacroscopy;  
Corneal Thickness,  
Histology, Localization 
Studies 
[27,29,73,74] 
Dehydration 10% Gelatin 
Primary Rat IPE cells; 
ARPE19 cell line 
RPE 
RPE Sheet 
Delivery 
Morphology;  
Proliferation assay; 
Live/Dead;  
Glutamate uptake;  
PIC expression 
Graft survival Histology 
Post-Implantation 
[30,31,75] 
DHT Gelatin 
Primary Corneal 
Endothelial 
Corneal 
Endothelium 
Endothelial Cell 
Sheet Delivery 
ICC; Cell morphology – [45] 
CS, chondroitin sulphate; DHT, dehydrothermal; GA, glutaraldehyde; GAG, glycosaminoglycan; ICC, immunocytochemistry; IHC, immunohistochemistry;  
IOP, intraocular pressure; IPE, iris pigment epithelial cells; m-TG, microbial transglutaminase; OCT, optical coherence tomography; PIC, pro-inflammatory cytokine; 
SEM, scanning electron microscopy; RPE, retinal pigment epithelial. 
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Whilst GA crosslinked structures have been used clinically [67], constructs have caused 
inflammation and calcification when implanted in vivo in rabbit osteochondral defects [57,76]. This 
has prompted investigation of alternative crosslinkers. One non-zero-length crosslinker of common 
interest is genipin [64], a natural product abundantly present in gardenia fruits, which has been shown 
to be 10,000 times less toxic than GA [77]. The reaction between gelatin and genipin is not well 
characterized but it has been proposed to occur in two distinct steps (Scheme Ι). In the first step 
(Scheme ΙA) rapid nucleophilic attack of a lysine amino group to the ring structure of genipin results in 
the opening of the dihydropyran ring and the formation of a tertiary amine. A subsequent slower 
reaction (Scheme ΙB) then results in the crosslinking process with nucleophilic substitution by a lysine 
amino group from a second fragment of gelatin [65]. These two independent reactions lead to the 
crosslinking of gelatin, a reaction which is slower than that of GA. Whilst genipin has been used in 
ocular research to crosslink chitosan in corneal tissue engineering, no studies investigating genipin 
crosslinked gelatin were identified in the field of ocular tissue engineering [78,79]. 
Scheme Ι. Crosslinking reaction of gelatin by genipin with: (A) primary reaction through 
Michael addition to form stable intermediate; and (B) secondary reaction with nucleophilic 
substitution of free lysine amine molecules into genipin activated ester. 
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2.1.2. Zero-Length Crosslinking 
One of the main disadvantages of non-zero-length crosslinking is that reagents built into the 
biomaterial are released upon degradation, which can potentially be a source of cell toxicity [57].  
Zero-length crosslinker reagents typically activate carboxylic acid groups and facilitate their reaction 
with amine residues, resulting in the formation of an amide bond (Scheme ΙΙ). The most common 
methods involve the use of acyl azide [80,81] and carbodiimide coupling [82]. These methodologies 
have been well developed in recent years although carbodiimide has been more widely employed than 
acyl azide coupling due to the toxicity of the hydrazine by-products [82]. 
One of the most well-used carbodiimide linkers is 1-ethyl-3-(3-dimethyl aminopropyl) carbodiimide 
(EDC) which activates the carboxylic acid residues of aspartic and glutamic acids and converts them 
into O-acylisourea groups (Scheme ΙΙ). Amide bonds can be formed by nucleophilic attack of free 
amine groups of lysine on the activated carboxylic acid, with a urea derivative as a leaving group. 
Possible side-reactions occur through the hydrolysis of the O-acylisourea group or the rearrangement 
of the O-acylisourea group into a stable N-acylurea derivate [82]. N-hydroxysuccinimide (NHS) can 
be used in combination with EDC, to activate the carboxylic acid group, which is in turn less 
susceptible to hydrolysis, and can increase the efficiency of the crosslinking reaction. An advantage of 
this technique is that all residues are water soluble, and can be easily washed out of the construct after 
crosslinking. This crosslinking approach has been successfully applied to RHC to produce robust  
bio-artificial corneal grafts, that have been evaluated in a phase I clinical trial [56].  
Scheme ΙΙ. Schematic of the mechanism of the crosslinking reaction between carboxylic 
acids and lysine, through activation with 1-ethyl-3-(3-dimethyl-aminopropyl)carbodiimide 
(EDC) and N-hydroxysuccinamide (NHS). The amide bond is formed directly between the 
two amino acids of gelatin with no linker in between. 
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A recent study comparing the biocompatibility of EDC crosslinking to that of GA, demonstrated 
that EDC treated gels produced lower interleukin-1β and tumour necrosis factor-α expression in iris 
pigment epithelial cultures, as well as higher cell viability after 2 days (see Table 1) [12,71]. The EDC 
treated gels were seen to be safe and did not elicit any adverse events after 12 weeks of implantation in 
the anterior chamber of a rabbit eye [12]. The effect of solvent composition on the EDC crosslinking 
process has also been investigated. Increasing the ethanol content of solvent mixtures increased the 
crosslinking efficiency and did not elicit any significant increase in interleukin-6 (IL6) expression or 
drop in proliferative capacity of retinal epithelial cells [21]. 
2.2. Enzymatic Crosslinking 
Recently, enzymes have been exploited to crosslink gelatin [16,17]. Calcium independent microbial 
transglutaminase catalyzes the formation of an amide bond between the carboxylic acid groups of 
glutamic acid and the ε-amino group of lysine [83]. This methodology has been used to produce 
bioadhesives suitable for treating retinal detachment [16]. Gelatin and microbial transglutaminase (mTG) 
were injected into the vitreous cavity of a rat model without the material eliciting structural or cellular 
damage to the retina. In addition, the gelatin-mTG adhesive was able to bind to bovine retinal tissue 
under wet conditions with lap-shear strengths comparable to other soft-tissue adhesives [16]. More 
recently gelatin-mTG adhesives have been evaluated for use in treating retinal tears in a rabbit  
model [17]. Gelatin-mTG complexes were seen to continue to adhere and seal retinal tears several days 
after administration with complete reattachment of the retina and without any inflammatory reactions. 
Other enzymes, such as tyrosinase, have also been evaluated in terms of gelatin crosslinking but have 
been found to form weaker gels [84]. 
2.3. Physical Crosslinking 
Physical crosslinking methods of gelatin have been based on the use of plasma [85], UV  
radiation [86,87] and dehydrothermal treatment (DHT) [45,88]. Whilst physical crosslinking has 
advantages in that no potentially cytotoxic chemicals are introduced to the system, a lack of control 
over the reaction kinetics of crosslinking, as well as lower degrees of crosslinking in this method may 
produce mechanically weaker constructs [80,88] compared to chemical or enzymatic crosslinking. 
Although not strictly crosslinking, several studies have looked to utilize gelatin carriers formed from 
dehydration of gelatin solutions [20,73,75]. Low modulus constructs made in this way [20,75] are well 
suited to applications requiring rapidly resorbed cell sheet carriers for ocular delivery (see Table 1). 
Both the IEP and molecular weight of gelatin have been investigated to evaluate the 
biocompatibility of dehydrated gelatin discs as carriers for corneal endothelial cells [29]. Gelatin with 
IEPs of 5.0 to 9.0 and several molecular weights in the range of 3 to 100 kDa were used to cast 
hydrogels disks which were subsequently dehydrated. The physiochemical and biocompatible 
properties of the transparent gels were assessed and the optimal gelatin disc carrier system was 
identified: gelatin with an IEP of 5.0 and molecular weight of 100 kDa. At the same molecular weight, 
gelatin with an IEP of 9.0 showed lower corneal endothelial compatibility suggesting that favorable 
cellular interactions occurred with gelatin that was negatively charged at physiological pH [29].  
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Whilst dehydrated gels with higher Bloom index can offer better mechanical properties in terms of 
mechanical strength and dissolution rate, they were seen to be less cell compatible when supplemented 
to the culture of retinal pigment epithelial (RPE) cells [30,31]. Higher Bloom gelatin discs induced 
higher levels of IL-6 and lower rates of proliferation of RPE cells suggesting that a higher Bloom 
index may increase cellular inflammatory reactions and reduce cell compatibility [31]. Investigations 
into sub-retinal RPE delivery using gelatin discs focused primarily on cannula delivery. It was noted 
that constructs made with low Bloom gelatin were too fragile to be delivered in vivo through a cannula 
into the sub-retinal space of a rabbit eye [30]. 
2.4. Chemical Modification of Gelatin 
Outside the field of ocular tissue engineering, alternative strategies have been devised to enhance 
the level of control and the biocompatibility of the crosslinking process. One such method has been to 
chemically modify gelatin to give a starting prepolymer that can be UV crosslinked, affording 
constructs with mechanical properties that can be easily modulated [89]. The most common method to 
achieve this has been to use methacrylic anhydride to functionalise free amino groups of lysine as 
methacrylamide groups (Scheme ΙΙΙ). Through dissolution in aqueous media with catalytic levels of 
photoinitiator, gelatin methacrylamide can be crosslinked with UV light [89,90]. 
Scheme ΙΙΙ. Methacrylation of gelatin to afford gelatin methacrylamide. Free amino 
groups of gelatin react with methacrylic anhydride in phosphate buffered saline solution 
(PBS) at 50 °C. The gelatin methacrylamide product can be photocrosslinked through the 
use of a photo activated radical initiator and UV light [89]. 
 
The mechanical properties of crosslinked constructs have been changed through tailoring the level 
of methacrylation during gelatin methacrylamide synthesis [89]. Further control over the physical 
properties has also been attained through changing parameters such as: the concentration of gelatin 
methacrylamide and photoinitiator; and the UV irradiance delivered to the construct [91]. In this 
system, relatively low levels of UV exposure are able to produce stable hydrogels, which has allowed 
cells to be encapsulated and cultured within gelatin methacrylamide gels [92,93]. Exposures typically 
of around 7 mW.cm
−1
 have been used for less than 1 min. to generate cell-laden hydrogels with no 
reports of any significant effect on cell viability [89,93,94]. UV crosslinking of gelatin methacrylamide 
also offers opportunities for photopatterning allowing micro-features to be included into crosslinked 
constructs, through the use of photomasks and molds [94–96]. 
Applying gelatin methacrylamide gels to clinical biology could offer an opportunity to explore the 
effects of both matrix compliance and topographical cues on cell phenotype. In addition, UV 
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crosslinking gelatin methacrylamide can form relatively transparent resultant hydrogels. These could 
offer real value in ocular tissue engineering, especially in producing 3D tissues such as the corneal 
stroma. Although gelatin methacrylamide has yet to be investigated in the field of ocular tissue 
engineering, the authors consider this to be an area of future consideration.  
3. Tailoring Gelatin-Based Materials to Ocular Applications 
Crosslinked gelatin biomaterials have found application in many ocular tissues: as a bio-adhesive to 
secure and stabilize retinal tissue [16,17], as a cell-sheet carrier for corneal endothelial cells [74], and 
as cellularised scaffolds for repair and regeneration of the corneal stroma (Figure 1) [19]. At the time 
of writing, only two relevant gelatin products could be identified, both used in bio-surgery: Gelfilm
®
, 
an absorbable film marketed for use in thoracic, ophthalmic and neuro- surgery [97] and Gelfoam
®
, a 
compressed gelatin sponge, marketed as a hemostatic device [98]. Current endeavors to develop 
gelatin-based biomaterials for regenerative medicine applications in ophthalmology are reported herein.  
Figure 1. Schematic representation of the eye; gelatin-based materials have found 
application in the repair of the ocular components shown above. 
 
3.1. Cornea 
The cornea exists as the multi-layered, transparent window covering the front of the eye [99]. The 
cornea is made up of six component layers: Epithelium; Bowman’s layer; Stroma; Descemet’s 
membrane; the newly described Dua’s layer and Endothelium [100]. Only the epithelium, stroma and 
endothelium are made up of cells, the structures of these three layers are shown in Figure 1. The cornea 
is responsible for a large proportion of the eyes’ refractive power, and thus its transparency is critical 
for normal function. A healthy cornea is avascular and immune privileged [101]. However in cases of 
Materials 2014, 7 3117 
 
trauma, burns and infectious disease, often vascularization and inflammation can occur which result in 
a loss of the transparency and immune privilege of the tissue [102]. 
Tissue engineered corneal tissues provide an alternative for patients suffering transplant rejection 
and also supplements the donor pool of corneal tissues [103]. The technology which has progressed the 
furthest is arguably that of the acellular recombinant human collagen scaffold which has had some 
success in clinical treatment of patients with corneal thinning [56,104]. In addition, scaffolds 
comprised of compressed collagen [8,48,49], amniotic membrane [105] and even decellularised 
corneas are currently under investigation [106]. 
Research into gelatin-based biomaterials for cornea tissue engineering is still preclinical and has 
mainly focused on providing substrates for cultivation and delivery of different corneal cell types [13]. 
These include the growth and delivery of corneal endothelial cells [73,74,107], growth of epithelial or 
limbal cells for corneal surface delivery [13,108], and investigation into the use of gelatin as a stromal 
replacement [18,19,69,108]. 
In addition, studies have examined the application of topical drugs to the ocular surface via gelatin 
particles [26,109–111] or by contact lenses containing immobilized gelatin particles loaded with 
hydrophilic protein [112]. 
3.1.1. Corneal and Limbal Epithelium 
Loss of the limbal epithelial stem cell (LESC) population can occur through trauma, burns, 
infectious or genetic disease and it is often associated with pain, inflammation and impaired  
vision [48]. LESC transplantation is often the only option for patients and involves grafting LESCs 
from a healthy donor eye, usually on an amniotic membrane carrier [113]. Whilst the procedure has 
shown success, biological variability of the amniotic membrane has produced varied levels of graft 
survival [6]. The search for new carriers has led to investigation into crosslinked gelatin biomaterials 
to provide low cost and effective solutions to this clinical problem. 
De la Mata and colleagues recently reported the use of a LESC carrier composed of chitosan and 
gelatin covalently bound through crosslinking with glutaraldehyde and subsequently reduced with 
sodium borohydride [13]. Introduction of chitosan was an attempt to mimic the glycosaminoglycan 
composition of the native limbus, thought to be important in maintaining the “stemness” of seeded 
LESCs. This work demonstrated that at an optimum ratio of chitosan to gelatin (20:80), LESCs 
maintained a more stem-like phenotype than those cultured on tissue culture plastic (TCP) [114].  
Cationised gelatin films have been used as a therapeutic bandage loaded with epidermal growth 
factor (EGF) to enhance wound healing in epithelial scars in an in vivo rabbit model [109]. Although 
cationised gelatin stabilized and controlled the release of epidermal growth factor, the films themselves 
did not have potential for further translation since they were too weak to be sutured in the rabbit model 
and required fixation through use of a soft contact lens. Additionally, the combination of a low water 
content hydrogel and the oxygen impermeable contact lens led to hypoxic conditions on the corneal 
epithelium and issues with re-epithelialization [109]. 
Another approach has been to chemically crosslink gelatin, collagen and hyaluronic acid with EDC 
and NHS in different ratios [115]. Hyaluronic acid is an important component of the extracellular 
matrix, which has been found to facilitate the adhesion and proliferation of corneal cells [116,117]. 
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Seeding epithelial cells upon films made of a 3:6:1 ratio of gelatin, collagen and hyaluronic acid 
respectively increased proliferation compared to TCP. The combination reported represents an 
interesting example of a complex crosslinked mixture with a high porosity allowing satisfactory 
diffusion of important small molecules.  
3.1.2. Corneal Stroma 
The main challenges in tissue engineering the corneal stroma lie in fabricating a fibrous 
extracellular matrix, sparsely populated with an even distribution of quiescent keratocytes and nerve 
fibres, into a single, strong, perfectly transparent construct [69]. Such a target would require either 
encapsulation or surface seeding of keratocytes upon a scaffold which would be supportive of a 
quiescent phenotype [118]. 
Mimura et al. [70], attempted to circumvent difficulties in handling keratocytes by instead culturing 
keratocyte precursors. Stromal cells were isolated and cultured as spheroids within a GA crosslinked 
gelatin matrix (Figure 2A). This work demonstrated a novel method of reconstructing the corneal 
stroma: the keratocyte precursor spheres not only tolerated the GA crosslinked hydrogels but 
differentiated into mesenchymal fibroblasts and neural cells. Implantation into a rabbit corneal stromal 
pocket (Figure 2B–F) showed no immune cell infiltration even after 4 weeks of implantation, with 
keratocytes presenting desirable surface markers by histological immunostaining (Figure 2G–H) [69]. 
Although cell spheres required centrifugation after surface seeding to produce an even dispersion of 
the keratocyte precursors, this study demonstrated both in vitro and in vivo biocompatibility of  
GA crosslinked gelatin.  
Hydrogels formed from covalently linking gelatin with hydroxypropyl chitosan have also been 
investigated for corneal stromal replacement [119], with a highly transparent and relatively permeable 
gel made to include chondroitin sulphate (CS), a linear anionic polysaccharide found in the corneal 
stroma [120]. It has been reported that introduction of CS improved gelatin hydrogel biocompatibility 
as seen by cell adhesion and proliferation data [18]. Lai et al. [18,19] have provided convincing 
evidence that incorporation of CS into gelatin hydrogels can enhance the biocompatibility of stromal 
replacement scaffolds. Firstly, the group demonstrated that increasing CS in the scaffold increased the 
total collagen and glycosaminoglycan (GAG) production by cultured rabbit corneal keratocytes 
without eliciting increased IL-6 expression [18]. However it was noted that the level of keratocan 
expression, an important biomarker of the keratocyte phenotype, was reduced in cells on scaffolds 
cultured on high CS content scaffolds. More recent studies have demonstrated that altering the 
crosslinking concentration (NHS-EDC) of gelatin–CS scaffolds significantly affected the fibronectin 
absorption, glucose permeability and keratocyte adhesion [19]. 
Yan and Gao [108,121] have reported investigations into the biocompatibility of gelatin-based 
electrospun membranes and the effect of fibre alignment upon keratocytes and epithelial cells. 
Keratocytes favoured aligned fibre scaffolds compared to random fibre orientations on gelatin-based 
scaffolds, and showed better proliferation [121] and keratocyte biomarker expression [108]. This work 
demonstrated that the use of scaffolds with instructive topographies, such as aligned electrospun 
scaffolds, could give rise to keratocytes expressing a more quiescent phenotype [122]. 
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Figure 2. Assessment of the in vivo biocompatibility of cultured corneal stromal cells with 
GA crosslinked gelatin. (A) Culture of primary corneal stromal cell spheroids seeded upon 
a GA crosslinked gelatin hydrogel; (B,C) Implantation of construct within intra-stromal 
pockets in the rabbit cornea; (D,E,F) Visual appearance of constructs 4 weeks after 
implantation showing; (D) Gelatin; (E) Keratocyte and gelatin; and (F) Keratocyte 
precursor and gelatin; (G) Histological analysis of the implants 4 weeks after implantation 
showing no immune cell infiltration of the gelatin implants in any group. Keratocyte 
precursor cells showing more intense staining for laminin, type I and type IV collagen, and 
vimentin, Scale bar = 100 μm; (H) Immunolocalization of CD34 positive or nestin positive 
cells within the transplanted keratocytes precursor gelatin implants 4 weeks after 
transplantation. Rhodamine (red colour) shows the transplanted labelled corneal keratocyte 
precursors in the gelatin hydrogels, and FITC (green colour) shows the CD34- or nestin- 
positive cells. Scale bar = 100 μm. Courtesy of Mimura et al. [70] and Molecular Vision. 
Copyright by Mimura (2008). The work was originally published in [70]. 
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3.1.3. Corneal Endothelium 
The corneal endothelium covers the posterior surface of the cornea and plays a critical role  
in regulating the water content of the stroma. Conditions in which the endothelium is disrupted  
(e.g., Fuchs dystrophy) [123] often require surgical intervention to replace the endothelium, normally 
with a donor endothelium [124]. Given the limitations of donor corneal material, many researchers in 
this area have attempted to develop cultivated cell-sheet implants which could potentially be used to 
repair and regenerate the damaged endothelium [8]. For a detailed overview of this field, readers are 
directed to an excellent review by Mimura et al. [125]. 
A large body of work investigating endothelial cell-sheet delivery has focused on delivering cell 
sheets derived from thermoreversible poly-N-isopropylacrylamide (pNIPAM) culture substrates [107]. 
Following a small thermal change, polymeric culture surfaces release intact cell sheets ready for 
implantation at the posterior cornea [27]. One significant challenge faced by groups working in this 
area is the handling and transport of the cell sheet. To this end gelatin has been thoroughly investigated 
as a carrier substrate [20,73,74]. 
Lai et al. [73,107] were one of the first teams or groups to explore in vivo the possibility of an 
endothelialised gelatin carrier for endothelial sheet delivery to the posterior cornea. Culture of primary 
human corneal endothelial cells (HCECs) on poly-NIPAM substrates generated an intact endothelial 
cell sheet, which was transferred to a gelatin carrier. The resultant constructs were delivered to a  
de-endothelialised rabbit cornea in vivo and monitored for 6 months [73]. A schematic diagram of this 
process is presented in Figure 3. The use of cast hydrogels which were air-dried without crosslinking 
resulted in high swelling and dissolution rates of the gelatin discs, which rapidly dispersed in the 
anterior chamber, leaving no solid constructs in the visual axis. Investigations of intraocular pressure 
(IOP) and corneal thickness as measures of ocular health demonstrated that gelatin could be used 
effectively in this application. The transplanted HCEC-gelatin construct effectively restored both the 
IOP and corneal thickness close to that of the healthy cornea. In contrast, rabbit corneas receiving the 
gelatin carrier alone presented no reduction in corneal swelling, showing no signs of improved water 
regulation. This indicates that the cellular component really is important in restoring the function of the 
corneal endothelium in vivo [73]. In addition Lai et al. [29] showed that by using different molecular 
weights and isoelectric points of gelatin the mechanical and biocompatibility properties of air dried 
gelatin sheets could be changed. 
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Figure 3. Schematic diagram of HCEC-gelatin sheet implantation reported by  
Lai et al. [73]. Primary endothelial cells were cultured upon a pNIPAM culture surface 
until confluent. The cell sheet was detached and transferred to a gelatin disc. The gelatin 
disc was implanted into the anterior chamber of the rabbit eye in which the endothelium 
had been removed surgically. The gelatin disc swelled localizing the corneal endothelial 
cells against the posterior surface of the cornea, where the cells proliferated and restored 
the cornea to health. Figure adapted from Hsiue et al. [74]. 
 
Whilst this study was a good starting point for the use of gelatin hydrogels as a HCEC carrier, the 
use of the dense air dried gelatin scaffold was associated with reduced flow of aqueous humor which 
disrupted the flow of nutrients to other tissues and which could result in increased ocular pressure.  
To increase perfusion of aqueous humor, efforts have been made to increase the porosity of HCEC 
carrier membranes [72]. Highly porous membranes were achieved using a stirring-freeze drying 
process followed by chemical crosslinking. These porous gelatin films were seen to degrade in less 
than one day in physiological conditions; it was hypothesized that this would reduce swelling in the 
anterior chamber and hence improve nutrient perfusion. 
Recently, it was further shown through a series of in vivo experiments that HCEC-gelatin constructs 
can be delivered to the target region effectively through a cannula. After delivery, corneal swelling 
occurring from de-endothelialisation was restored. The gelatin carriers dissolved rapidly within  
2 weeks of implantation with no signs of biological reactions in the anterior chamber in test or control 
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groups. These developments provide good evidence that this approach may be suitable for endothelial 
regeneration [27]. 
Other researchers have attempted to culture HCEC directly onto gelatin carrier films. Comparing 
dehydrothermally crosslinked gelatin sheets to atelocollagen, a water soluble form of collagen, the 
gelatin scaffolds were seen to offer better elasticity, transparency and permeability. However, in 
assessing the biocompatibility, the gelatin sheets were coated in collagen, making an accurate 
comparison between the two materials difficult [45]. 
Gelatin carrier sheets are able to play an important role in delivering endothelial cell sheets to the 
diseased corneal endothelium. This method has distinct advantages in ensuring there is no residual 
carrier material left in the anterior chamber, a challenge often faced when long lasting carriers such as 
amniotic membrane are employed [126]. 
3.2. Retinal Pigment Epithelium 
The retinal pigment epithelium (RPE) is a highly specialized tissue, situated between the choroid 
and the neural retina. The tissue performs both metabolic and transport functions critical to 
maintaining the health of the neural retina [127]. These processes include transport of nutrients and 
waste products to and from photoreceptor cells [128]. Each cuboidal pigmented epithelium is 
estimated to support around 20 photoreceptors [129].  
Dry age-related macular degeneration (AMD) is one of largest cause of blindness in developed 
nations. Prevalence of the disease continues to rise with the increase in average life expectancy. Loss 
of vision in dry AMD is the result of degeneration of photoreceptors occurring as RPE cells with 
which they are associated deteriorate and die. With the exception of macular translocation, there are 
currently no therapies available for the treatment of dry-AMD [1]. 
One strategy currently being explored for the treatment of dry AMD, amongst other macular 
dystrophies is that of RPE transplantation. Such a therapy would involve the delivery of donor RPE 
cells, or allogeneic RPE progenitors beneath the neural retina, in order to restore the damaged  
tissue [75]. Whilst a bolus injection of RPE cells into the sub-retinal space has been demonstrated to be 
effective [130], issues with cellular positioning and cell survival after injection have been  
reported [131]. Strategies to overcome these hurdles have included the use of injectable cell laden 
hydrogels to prevent death of cells by reflux [132] or through generating RPE sheets [133] that can be 
transplanted either with [134] or without a carrier system [134,135]. A schematic of the transplantation 
of RPE-carrier sheets is presented in Figure 4. 
There are several literature reports of the use of gelatin as an RPE sheet carrier which have offered 
signs of success. Hsiue et al. [75] reported initial success with a gelatin-cell construct in which sheets 
of confluent RPE cells were sandwiched between two gelatin discs. One study investigated an array of 
treatments for the sterilization of gelatin membrane carriers including: hydrogen peroxide gas plasma, 
ethylene oxide gas, and γ-ray irradiation, to assess their cytotoxicity towards RPE cells. Scaffolds 
sterilized with, low dose γ-ray irradiation (16.6 kGy), were seen to be least cytotoxic in vitro and well 
tolerated when injected into the sub-retinal space in a rabbit model, with no signs of inflammation. The 
effects of Bloom strength have also been assessed in the gelatin-RPE-gelatin sandwich. Lower Bloom 
gelatins were generally easier to deliver through a cannula to the sub-retinal space, and dissolved faster 
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and were cytocompatible relative to higher Bloom gelatin [30]. Lai et al. [31] examined the cell 
compatibility of gelatin Bloom strengths and suggested that lower Bloom strengths were associated 
with lower levels of inflammation as measured by the production of the pro-inflammatory cytokine IL-6. 
Figure 4. Potential treatment of RPE degeneration with RPE sheet-gelatin constructs.  
(A) Schematic of healthy eye, presenting an intact retinal pigment between the retina and 
the choroid; (B) degenerated RPE cell layer leading to potential loss of vision; (C) small 
portion of retina detached from RPE layer through introduction of fluid in the sub-retinal 
space; (D) cell sheet and carrier introduced into sub-retinal space through cannula delivery; 
(E) vitreous replacement fluids used to restore intraocular pressure and position detached 
portion of retina back in contact with implant. 
 
Both GA and EDC crosslinked gelatin membranes have been investigated for retinal epithelial sheet 
tissue engineering [71]. A comparison of the biocompatibility of the two crosslinkers demonstrated 
that EDC was less cytotoxic, as demonstrated by a proliferation assay. In addition ARPE-19 cells 
expressed higher levels of IL6 when cultured on GA crosslinked gelatin. 
An evaluation of the effect of crosslinker concentration of EDC (0–0.4 mmol EDC/mg gelatin) on 
physical and biocompatibility properties showed that increased crosslinker concentrations decreased 
water solubility and collagenase digestion times. Higher concentrations of EDC (0.1–0.4 mmol) 
reduced the biocompatibility of the membranes as measured through an MTT assay. The effect of 
solvent composition was also investigated showing that the crosslinking density could be controlled 
using different ethanol to water ratios [21]. 
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3.3. Bio-Adhesives for Retinal Tears 
The investigation of gelatin-based materials as bio-adhesives for the treatment of retinal detachment 
has been of interest to a number of research groups in this area [136]. Studies have investigated the 
potential use of microbial transglutaminase (m-TG) crosslinked gelatin as a bio-adhesive [16,17]. 
Enzymatic crosslinking has been shown to be well suited to this application given the need for in situ 
gelling. Gelatin solutions 20% (w/v) were made up and mixed for 1 minute with a 20% (V/V) solution 
of microbial transglutaminase [16]. After injection of the bio-adhesive into the vitreous cavity of a rat 
model, there were no signs of any inflammatory or antigenic response after 2 weeks, demonstrating the 
in vivo biocompatibility of the adhesive. With a more concentrated solution of the adhesive, an in vitro 
lap shear assessment showed that a lap shear moduli of 12–25 kPa could be achieved, similar to other 
soft tissue adhesives (12–20 kPa) [16]. 
Gelatin solutions 15% (w/v) with microbial transglutaminase have been used in vivo in a vitrectomy 
model (simulating retinal detachment) [137]. The bio-adhesive was seen to successfully cover a retinal 
tear model 7 days after administration. Optical coherence tomography demonstrated that the gelatin 
material had completely disappeared by day three. In addition, electroretinograms showed no adverse 
effects of the gelatin–mTG adhesive on retinal function. A schematic of how the bioadhesive could be 
used for the repair of retinal tears is shown in Figure 5. 
Figure 5. Potential treatments of retinal tears with m-TG. (A) Retinal tear initially forms; (B) if 
large enough vitreous humor diffuses into sub-retinal space exacerbating the tear and forcing 
more retinal tissue away from the RPE; (C) sub-retinal vitreous humor aspirated; (D) a 
homogenous mixture of gelatin and m-TG solutions mixed and applied to the sub-retinal space; 
(E) normal ocular pressure restored through infusion of vitreous replacement fluid. 
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4. Opportunities for Future Work 
Gelatin-based materials have been most successful in ocular tissue engineering as cell sheet carriers, 
with effective delivery of both corneal endothelial sheets to the posterior cornea [20], and also RPE 
sheets to the sub-retinal space [138]. In both applications dehydrated gelatin discs were successfully 
delivered through a cannula and were swiftly resorbed in vivo, with no adverse biological events reported. 
In addition to altering the bulk chemistry of gelatin, the process of crosslinking also changes both 
the matrix compliance and potentially the topography of the constructs [139]. The work described in 
this review largely attributes changes in biocompatibility to the toxicity and antigenicity of the 
chemical changes [12]. Future work to evaluate the effect of matrix elasticity of gelatin grafts is an 
important step to develop a deeper understanding of the biocompatibility of gelatin. Gelatin 
methacrylamide offers a gel-based system with tunable matrix stiffness, which can be controlled 
without significantly changing the chemical composition [95]. Generation of gelatin methacrylamide 
gels of different elastic moduli [89] has been previously demonstrated. In the authors opinion this 
material would be an effective tool in determining the optimum material properties for application in 
ocular tissue engineering. 
Photocrosslinkable gelatin scaffolds in recent years have been a popular choice for use in a range of 
tissue engineering applications including cartilage repair [140], generating blood vessels [93] and also 
cardiac tissue development [141]. However to the authors’ knowledge this highly versatile material has 
yet to be explored in ocular tissue engineering. The authors hypothesize that the additional  
spatial control of crosslinking offered through photo- patterning [94,142], molding [141] and 
stereolithography [95] will provide a range of opportunities in both creating candidate scaffolds for 
stromal tissue engineering and also in exploring the influence of matrix compliance and topography on 
ocular cell types. 
5. Summary 
Crosslinked gelatin scaffolds make up a small but important part of the ocular tissue engineering 
landscape. Gelatin’s similarity to collagen offers an excellent, low cost starting substrate that if 
crosslinked using appropriate methods could provide lower antigenic and immunogenic risk than its 
parent material. 
Gelatin and its derivatives have been used as potential scaffolds for corneal epithelium [13], corneal 
endothelium [20] and retinal pigment epithelium [21], as a bioartificial corneal stroma [19] and as a 
potential bioadhesive in treatment of retinal detachment [17]. The range of crosslinking options  
used to strengthen gelatin scaffolds in this field to date is extensive. There is good evidence  
to suggest that zero-length crosslinkers may be preferable in terms of both cell compatibility and 
biocompatibility [71]; the authors’ review of recent literature suggests this is a more popular method 
than non-zero-length crosslinking. Whilst there may be uses for glutaraldehyde to crosslink matrices, 
such as fragile electrospun matrices which are short lived in aqueous solutions [60], the risk of cell 
toxicity of excipients could be a potential issue. 
The utility of dehydrated gelatin discs in ocular tissue engineering has been dominated by 
application as a cell sheet carrier in the delivery of either endothelial cell sheets to the posterior  
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cornea [27], or retinal pigment epithelial cells to the sub-retinal space [30,75]. These gelatin carriers 
have provided effective cell delivery in vivo and have been well-tolerated with few adverse events 
reported [27].  
Over the last decade the rise in popularity of partial thickness corneal transplants [123,143] has led 
to an opportunity to supplement the insufficient donor cornea pool with tissue engineered partial 
thickness grafts. To date there have been few applications of gelatin in this area and studies have 
examined cell toxicity [19] rather than creation of functional tissues. One issue that is likely to have 
limited research in this area is the difficulty in forming even dispersions of corneal stromal cells 
through gelatin matrices, with the harsh or lengthy crosslinking processes not amenable to producing 
cell laden constructs. Developments in other areas of tissue engineering have shown that photo 
crosslinkable gelatin products can be used to good effect to create cell-laden hydrogels [94,95]. The 
application of photo crosslinkable gelatin in corneal stromal tissue engineering is foreseen by the 
authors as being an area which must be investigated, particularly if gelatin-based materials are to fulfil 
their potential in stromal tissue engineering. 
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